Atopic Dermatitis

FDA Delays Approval for Abrocitinib for Atopic Dermatitis
July 22, 2021

The FDA did not meet the PDUFA goal date for abrocitinib (PF-04965842; Pfizer), a potential treatment of moderate to severe atopic dermatitis in adults and adolescents.

FDA Decision Delayed for Baricitinib for Atopic Dermatitis
July 21, 2021

The FDA has decided to delay the PDUFA goal date for baricitinib for treatment of adults with moderate to severe atopic dermatitis.

Systemic Treatment for Pediatric AD
July 19, 2021

New and forthcoming options bring opportunity for optimizing patient care.